Pharmaceutical companies are increasingly involved in the field of international health (the fight against AIDS, tuberculosis , etc.). What is their role, what actions do they put out? Are they able to cooperate with States, NGOs, international organizations and private foundations? Read More
Since the end of the 1990s, multinational firms — mainly pharmaceutical companies — have been very active in the global health sector. Now, these same firms have formed numerous international public-private partnerships. What is the role of these partnerships and what actions do they implement? Are they capable of co-operating with States, NGOs, international organisations and private foundations?
Focusing on the fight against HIV/AIDS, tuberculosis, malaria and neglected tropical diseases — issues that originally prompted international co-operation — this book charts the introduction of companies into global health governance via institutional organisations and market co-operation mechanisms. The author shows that this has been a gradual process through which these companies, which were originally autonomous actors, have become subject to regulations and ultimately transformed into governance partners.
This volume provides a unique look at the participation of economic multilateral actors and their ability to alter the functioning of global health governance.